These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27714642)

  • 41. Cangrelor: A New Route for P2Y12 Inhibition.
    Sible AM; Nawarskas JJ
    Cardiol Rev; 2017; 25(3):133-139. PubMed ID: 28379902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Why we need intravenous antiplatelet agents.
    Tyler JM; Burris RJ; Seto AH
    Future Cardiol; 2016 Sep; 12(5):553-61. PubMed ID: 27255111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching between P2Y
    Capranzano P; Capodanno D
    Vascul Pharmacol; 2019 May; 116():4-7. PubMed ID: 30876967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cangrelor for the treatment of patients with Arterial Thrombosis.
    Tantry U; Chaudhary R; Kubica J; Bliden K; Gurbel PA
    Expert Opin Pharmacother; 2018 Aug; 19(12):1389-1398. PubMed ID: 30102083
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors.
    Adamski P; Koziński M; Ostrowska M; Fabiszak T; Navarese EP; Paciorek P; Grześk G; Kubica J
    Thromb Haemost; 2014 Aug; 112(2):224-42. PubMed ID: 24763899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cangrelor: an emerging therapeutic option for patients with coronary artery disease.
    Kubica J; Kozinski M; Navarese EP; Tantry U; Kubica A; Siller-Matula JM; Jeong YH; Fabiszak T; Andruszkiewicz A; Gurbel PA
    Curr Med Res Opin; 2014 May; 30(5):813-28. PubMed ID: 24393016
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; Lagerqvist B; Erlinge D; Varenhorst C; James S
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):151-157. PubMed ID: 30698669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials.
    Eisen A; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Int J Cardiol; 2018 Jan; 250():49-55. PubMed ID: 29030140
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cangrelor in patients undergoing cardiac surgery: the BRIDGE study.
    Voeltz MD; Manoukian SV
    Expert Rev Cardiovasc Ther; 2013 Jul; 11(7):811-6. PubMed ID: 23895024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.